PR Newswire Clinical TrialsOriginal article
TAXIS Pharmaceuticals Receives NIH SBIR Grant to Advance Development of Novel Antibiotic Class for Clostridioides difficile Infections
Positive
AI Analysis
Summary
TAXIS Pharmaceuticals received an NIH SBIR grant to support development of a novel narrow-spectrum antibiotic targeting hypervirulent C. difficile strains, marking the company's third such award in over two years.
Outcome Details
NIH SBIR grant awarded
Importance:3/10
Sentiment:
0.60
NIH SBIR grantantibiotic developmentC. difficilenarrow-spectrum therapyfunding
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on August 17, 2026 12:29 PM